

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

TEVA PHARMACEUTICALS USA, INC.,  
Petitioner

v.

CORCEPT THERAPEUTICS, INC.  
Patent Owner

---

Case PGR2019-00048  
Patent No. 10,195,214 B2

---

**DECLARATION OF WILLIAM H. MILLIKEN IN SUPPORT OF  
PETITIONER'S MOTION FOR *PRO HAC VICE* ADMISSION**

I, William H. Milliken declare as follows:

1. I am an Associate with the law firm of Sterne Kessler Goldstein & Fox PLLC. I represent and advise Petitioner Teva Pharmaceuticals USA, Inc. (“Teva”) in connection with the above-captioned post grant review (“PGR”) proceeding. I also represent Teva in connection with the underlying district court litigation (*Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc.*, No. 1:18-cv-03632 (D.N.J.)) on the patent at issue in this PGR proceeding, 10,195,214 (“the ’214 patent”).

2. I have been a member in good standing of the Bars of the State of Tennessee and the District of Columbia since 2014 and 2016, respectively. I am admitted to practice in several U.S. district courts, the U.S. Court of Appeals for the Federal Circuit, the U.S. Court of Appeals for the First Circuit, the U.S. Court of Appeals for the Ninth Circuit, and the Supreme Court of the United States.

3. I have not been suspended or disbarred from practice before any court or administrative body.

4. No sanction or contempt citation has been imposed against me by any court or administrative body.

5. I have never had an application for admission to practice before any court or administrative body denied.

6. I practice litigation, primarily patent litigation, and have done so

throughout my career as an attorney. I have litigated dozens of patent cases across the country, including in the U.S. District Court for the District of New Jersey; the U.S. District Court for the District of Delaware; and the U.S. District Court for the Eastern District of Texas. I have also briefed and argued cases in the U.S. Court of Appeals for the Federal Circuit.

7. I have extensively reviewed the '214 patent, its prosecution history and related materials, and the Patent Owner's infringement contentions served in the litigation against Teva. Additionally, I was the primary drafter of Petitioner's invalidity contentions in the litigation, and accordingly have gained significant familiarity with the invalidity issues in that case. These issues significantly overlap with the corresponding issues in this PGR proceeding. My involvement in the concurrent litigation has made me very familiar with the proposed invalidity grounds and the cited references in this proceeding.

8. In this PGR proceeding, I have worked with lead counsel and backup counsel named in this proceeding to identify and analyze the references relied upon in the petition and to assist with drafting the petition.

9. The prior-art references at issue in the PGR proceeding are also relevant in the underlying litigation in the case against Teva, and I have reviewed a vast amount of additional, related prior art for the invalidity contentions in the district-court litigation.

10. I have conferred with Dr. Greenblatt, and I thoroughly understand Dr. Greenblatt's testimony related to prior-art publications cited in this PGR proceeding.

11. Since 2016, I have represented Petitioner in connection with multiple patent litigations regarding various technologies, including, but not limited to, the mifepristone drug product at issue in this PGR. This includes the following litigations:

*Allergan Inc. v. Teva Pharmaceuticals USA, Inc. et al.*,  
No. 2:15-cv-01455 (E.D. Tex.);

*Warner Chilcott (US), LLC et al. v. Teva Pharmaceuticals USA, Inc. et al.*,  
No. 2:15-cv-01471 (E.D. Tex.);

*Horizon Pharma Ireland Limited et al. v. Actavis Laboratories, UT, Inc.*,  
No. 1:14-cv-07992 (D.N.J.);

*Horizon Pharma Ireland Limited et al. v. Actavis Laboratories UT, Inc. et al.*, No. 1:15-cv-07742 (D.N.J.);

*Horizon Pharma Ireland Limited, et al. v. Actavis Laboratories UT, Inc. et al.*, No. 1:16-cv-00645 (D.N.J.);

*Horizon Pharma USA, Inc. et al. v. Actavis Laboratories UT, Inc. et al.*,  
No. 1:16-cv-05051 (D.N.J.);

*Horizon Pharma USA, Inc. et al. v. Actavis Laboratories UT, Inc.*,  
No. 1:17-cv-03342 (D.N.J.);

*Sun Pharma Global FZE et al. v. Teva Pharmaceuticals USA, Inc.*,  
No. 1:18-cv-01552 (D. Del.);

*Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.*,  
No. 1:18-cv-00560 (D. Del.);

*Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.*,

No. 1:18-cv-00651 (D. Del.); and

*Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc.*,  
No. 2:18-cv-03632 (D.N.J.)

12. Through this work, I have developed in-depth knowledge of the relevant issues in this proceeding. This knowledge includes my analysis of a significant number of patents, articles, books, and other materials regarding these technologies. My experience also includes knowledge gained from working closely with several technical experts from academia and industry. And I have participated in many meetings with Teva's in-house employees regarding various technologies and applications, including, for example, as related to mifepristone.

13. Within the past three years, I have not requested to appear *pro hac vice* before the Office.

14. I have read and will comply with the Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials set forth in part 42 of the Code of Federal Regulations.

15. I understand that I will be subject to the USPTO Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 *et seq.* and disciplinary jurisdiction pursuant to 37 C.F.R. § 11.19(a).

16. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true. I further declare that these statements were made with the

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.